Diabetes medications and cardiovascular outcome trials: Lessons learned.
Where this comes from
- Record sourced from PubMed, PMID 28985176.
- Also identified by DOI 10.3949/ccjm.84gr.17006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.
Medical subject headings
- Cardiovascular Diseases
- Hypoglycemic Agents